Interfraction interval does not affect survival of patient with non- small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: A multivariate analysis of 1076 RTOG patients

International Journal of Radiation Oncology Biology Physics

Volumn 44, Issue 2, 1999, Pages 327-331

  Werner Wasik, Maria ^a   Scott, Charles ^b   Graham, Mary L ^c   Smith, Colum ^d   Byhardt, Roger W ^e   Roach III, MacK ^f   Andras, E James ^g  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d TOM BAKER CANCER CENTRE   (Canada)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Radiological Associates of Sacramento Medical Group Inc   (United States)

Author keywords

Chemotherapy; Esophagitis; Hyperfractionation; Lung cancer; Radiotherapy

Indexed keywords

CISPLATIN; ETOPOSIDE; VINBLASTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; ESOPHAGITIS; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 0032956133     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00031-0     Document Type: Article

References (20)

1. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with >69.6 Gy in favorable patients with stage III non-small cell lung carcinoma. Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 8:1990;1543-1555.
2. Perez C.A., Pajak T.F., Rubin P., et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer. 59:1987;1874-1881.
3. Sause W., Scott C., Taylor S., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588 Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer . J Natl Cancer Inst. 87:1995;198-205.
4. Byhardt R.W., Scott C.B., Ettinger D.S., et al. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15. Cancer. 75:(9):1995;2337-2344.
5. Lee J.S., Scott C., Komaki R., et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer Radiation Therapy Oncology Group Protocol 91-06 . J Clin Oncol. 14:1996;1055-1064.
6. Komaki R., Scott C., Ettinger D., et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer Radiation Therapy Oncology Group (RTOG) 92-04 . Int J Radiat Oncol Biol Phys. 38:(1):1997;149-155.
7. Jeremic B., Shibamoto Y. Effect of Interfraction Interval in Hyperfractionated Radiotherapy with or without Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 34:1996;303-308.
8. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
9. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:1959;719-748.
10. Cox D.R. Regression models and life-tables. J R Stat Soc B. 4:1972;187-202.
11. Mehta C., Patel N. StatXact 3 for Windows User Manual . 1996;Cambridge, CYTEL Software.
12. Fowler J.F. Intervals between multiple fractions per day-Differences between early and late reactions. Acta Oncol. 27:1988;181-183.
13. Thames H.D., Peters L.J., Ang K.K. Time-dose considerations for normal-tissue tolerance. Front Radiat Ther Oncol. 23:1989;113-117.
14. Nguyen T.D., Demange L., Froissart D., et al. Rapid hyperfractionated radiotherapy. Clinical results in 178 advanced squamous cell carcinomas of the head and neck. Cancer. 56:1985;16-19.
15. Cox J.D., Pajak T.F., Marcial V.A., et al. ASTRO plenary Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: Results from Radiation Therapy Oncology Group Protocol 8313 . Int J Radiat Oncol Biol Phys. 6:1991;1191-1195.
16. Saunders M.I., Dische S., Grosch E., et al. Experience with CHART. Int J Radiat Oncol Biol Phys. 21:1991;871-878.
17. Hermens A.F., Barendsen G.W. Changes of cell proliferation characteristics in a rat rhabdomyosarcoma before and after X-irradiation. Eur J Cancer. 5:1969;173-189.
18. Jeremic B., Shibamoto Y., Acimovic L., et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for Stage III nonsmall-cell lung cancer. J Clin Oncol. 13:1995;452-458.
19. Jeremic B., Grujicic D., Antunovic V., et al. Hyperfractionated radiation therapy followed by multiagent chemotherapy in patients with malignant glioma A Phase II study . Int J Radiat Oncol Biol Phys. 30:1994;1179-1185.
20. Nelson D.F., Curran W.J., Scott C., et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma-possible advantage observed at 72.0 Gy in 1.2 Gy BID fractions: Report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys. 25:1993;193-207.